BioWorld MedTech

Jan. 22, 2016

Firm aims for Strong position in molecular dignsotics marts: Biotheranostics spins out from Biom rieux with $32M funding

Staff Writer Biotheranostics (San Diego), a specialist in the molecular diagnostics for cancer market, said it raised $32 million and will be spun out from Biomérieux SA (Marcy-l'Étoile, France). The financing was led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and Healthquest Capital. Read More

Inside the Beltway: FDA cybersecurity workshop shows many issues unresolved

No device fails: At Least in one Case: Fourth artificial heart patiient in clinical trial dies; Carmat to begin pivotal trial

Exosome launchesRNA-based lung cancer test

Financings: Great Basin Scientific to convert remaining Series C warrants

Ageements/contracts: Centinel is cleared for Altos on the cervical-thoracic spine

Briefly noted

Daily M&A: Amarantus inks plan to merge Dx unit with Avant

Products

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 20, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 20, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...